logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Modernatx, Inc.


USPTO Granted Patents = 229



Trademarks = 97

Forward Citations = 3,922

Loading Chart...
Loading Chart...

196 inventors (with patents filed for the assignee):

goldMedal Kerry Benenato (57 out of 59 patents)

silverMedal Giuseppe Ciaramella (53 out of 53 patents)

bronzeMedal Stephen G Hoge (52 out of 54 patents)

4.  Vladimir Presnyak (37 out of 40 patents)

5.  Ellalahewage Sathyajith Kumarasinghe (36 out of 37 patents)

6.  Iain McFadyen (31 out of 31 patents)

7.  Joshua P Frederick (27 out of 27 patents)

8.  Sunny Himansu (27 out of 27 patents)

9.  Sayda Mahgoub Elbashir (25 out of 56 patents)

10.  Ailin Bai (22 out of 28 patents)

11.  Stephane Bancel (22 out of 31 patents)

12.  Eric Yi-Chun Huang (21 out of 21 patents)

13.  Tirtha Chakraborty (20 out of 43 patents)

14.  Antonin De Fougerolles (20 out of 20 patents)

15.  Justin Guild (19 out of 22 patents)


Core Competencies:
In Vitro Transcription
RNA Vaccines
Engineered Nucleic Acids
Lipid Nanoparticles
Modified Nucleotides
Therapeutic Agents
Polynucleotides
High-Purity RNA
Intracellular Delivery
mRNA Therapeutics
Vaccine Formulation
RNA Polymerase Variants

229 patents:

1. 12460259 - Fed-batch in vitro transcription process (2025-11-04),
2. 12453766 - RSV RNA vaccines (2025-10-28),
3. 12428577 - Methods of monitoring in vitro transcription of mRNA and/or post-in vitro transcription processes (2025-09-30),
4. 12419957 - Delivery and formulation of engineered nucleic acids (2025-09-23),
5. 12409347 - Betacoronavirus mRNA vaccines (2025-09-09),
6. 12409226 - Delivery and formulation of engineered nucleic acids (2025-09-09),
7. 12409218 - Influenza vaccine (2025-09-09),
8. 12404232 - Compounds and compositions for intracellular delivery of therapeutic agents (2025-09-02),
9. 12403336 - Betacorona virus mRNA vaccines (2025-09-02),
10. 12403335 - Betacoronavirus MRNA vaccines (2025-09-02),
11. 12396961 - Compounds and compositions for intracellular delivery of agents (2025-08-26),
12. 12385034 - Methods and apparatus for filtration (2025-08-12),
13. 12383508 - High-purity peg lipids and uses thereof (2025-08-12),
14. 12377136 - Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria (2025-08-05),
15. 12364763 - Delivery and formulation of engineered nucleic acids (2025-07-22),
ModernaTX, Inc. is a biotechnology company that focuses on the discovery, development, and commercialization of messenger RNA (mRNA) therapeutics and vaccines. Their research and innovations aim to harness the power of mRNA to provide a new class of medicines for patients. ModernaTX develops mRNA-based treatments spanning various therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and more.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

...
229 Patents

#14 in Cambridge, MA

#107 in Massachusetts

#1,758 in US

#3,620 in the World

...
Cambridge, MA, United States of America

Modernatx, Inc.

Forward Citations = 3,922

196 inventors:

goldMedal Kerry Benenato (57 out of 59 patents)

silverMedal Giuseppe Ciaramella (53 out of 53 patents)

bronzeMedal Stephen G Hoge (52 out of 54 patents)

4.  Vladimir Presnyak (37 out of 40 patents)

5.  Ellalahewage Sathyajith Kumarasinghe (36 out of 37 patents)

Please report any incorrect information to support@idiyas.com
Loading…